| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10040202 | HBV | ENSG00000157404.17 | protein_coding | KIT | Yes | No | 3815 | P10721 |
| TVIS10040086 | HBV | ENSG00000157404.17 | protein_coding | KIT | Yes | No | 3815 | P10721 |
| TVIS30010849 | HIV | ENSG00000157404.17 | protein_coding | KIT | Yes | No | 3815 | P10721 |
| TVIS20037373 | HPV | ENSG00000157404.17 | protein_coding | KIT | Yes | No | 3815 | P10721 |
| TVIS20039601 | HPV | ENSG00000157404.17 | protein_coding | KIT | Yes | No | 3815 | P10721 |
| TVIS44012431 | HTLV-1 | ENSG00000157404.17 | protein_coding | KIT | Yes | No | 3815 | P10721 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | KIT |
|---|---|
| DrugBank ID | DB00398 |
| Drug Name | Sorafenib |
| Target ID | BE0000453 |
| UniProt ID | P10721 |
| Regulation Type | antagonist |
| PubMed IDs | 17545544; 17102120; 17229632; 17272980; 17178882; 20586710 |
| Citations | Guida T, Anaganti S, Provitera L, Gedrich R, Sullivan E, Wilhelm SM, Santoro M, Carlomagno F: Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res. 2007 Jun 1;13(11):3363-9.@@Koch CA, Gimm O, Vortmeyer AO, Al-Ali HK, Lamesch P, Ott R, Kluge R, Bierbach U, Tannapfel A: Does the expression of c-kit (CD117) in neuroendocrine tumors represent a target for therapy? Ann N Y Acad Sci. 2006 Aug;1073:517-26.@@Lierman E, Lahortiga I, Van Miegroet H, Mentens N, Marynen P, Cools J: The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors. Haematologica. 2007 Jan;92(1):27-34.@@Cascone T, Gridelli C, Ciardiello F: Combined targeted therapies in non-small cell lung cancer: a winner strategy? Curr Opin Oncol. 2007 Mar;19(2):98-102.@@Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006 Dec 15;66(24):11851-8.@@Iyer R, Fetterly G, Lugade A, Thanavala Y: Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother. 2010 Aug;11(11):1943-55. doi: 10.1517/14656566.2010.496453. |
| Groups | Approved; Investigational |
| Direct Classification | Diarylethers |
| SMILES | CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1 |
| Pathways | Sorafenib Metabolism Pathway |
| PharmGKB | PA7000 |
| ChEMBL | CHEMBL1336 |
